Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Evaluating a triplet regimen for patients with relapsed or refractory MM after lenalidomide therapy

Posted by on Oct 1, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study examined if PBD (pomalidomide, bortezomib, dexamethasone) was safe and effective in patients with multiple myeloma after lenalidomide (Revlimid) treatment. The authors concluded that pomalidomide improved survival without tumor growth or spread but increased side effects. Some background...

Read More

Looking for patients with relapsed or unresponsive multiple myeloma to try allogeneic CAR-T cell therapy

Posted by on Sep 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial is evaluating the safety and effectiveness of allogeneic CAR-T cell therapy (ALLO-715) in patients with multiple myeloma (MM) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This trial is recruiting in Denver, CO. The details Chimeric...

Read More

Nivolumab in previously treated advanced non-small cell lung cancer – what is the long-term outlook for survival?

Posted by on Sep 16, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated survival rates in advanced non-small cell lung cancer (NSCLC) after nivolumab (Opdivo) treatment.  They found that nivolumab was associated with longer survival time in patients that responded to treatment.  Some background Lung cancer (LC) is one of the most common cancers worldwide. Non-small...

Read More

Stem cell transplant after blinatumomab in patients with relapsed or unresponsive acute lymphoblastic leukemia

Posted by on Sep 13, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes for patients who underwent allogeneic hematopoietic stem cell transplant after treatment with blinatumomab.  This study concluded that survival was driven by the response to study treatment and by salvage status regardless of transplant status.   Some...

Read More

Evaluating pembrolizumab for patients with reoccurring classical Hodgkin’s lymphoma

Posted by on Sep 2, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with classical Hodgkin’s lymphoma (cHL) that came back after initial treatment. This study concluded that pembrolizumab was effective for these patients, with manageable side effects. Some background First-line chemotherapy is highly...

Read More

Evaluating Kd and Vd chemotherapy for patients with relapsed or refractory multiple myeloma

Posted by on Aug 27, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study compared the effectiveness of Kd (carfilzomib, dexamethasone) chemotherapy to Vd (bortezomib, dexamethasone) chemotherapy in patients with multiple myeloma (MM). This study found that Kd improved survival outcomes and had fewer side effects compared to Vd chemotherapy for these patients. Some background Multiple...

Read More

Evaluating nivolumab plus brentuximab vedotin for patients with relapsed or unresponsive primary mediastinal large B-cell lymphoma

Posted by on Aug 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....

Read More

Searching for participants with high risk relapsed or unresponsive Hodgkin lymphoma to try a treatment combination.

Posted by on Jul 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) after stem cell transplant in patients with high risk relapsed or refractory Hodgkin lymphoma (RRHL). The main outcome that will be measured is progression-free survival. This trial is recruiting in multiple locations in the United States. The...

Read More

Looking for participants with advanced colorectal cancer to test a new combined treatment

Posted by on Jul 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of liposomal irinotecan (LI; Onivyde) and rucaparib (Rubraca) in treating patients with advanced colorectal cancer. The main outcome to be measured will be the toxicity and tumor response to the treatment. This trial is being conducted in Arizona, Georgia, Minnesota, and Utah, US. The...

Read More